These documents have been proactively released by the Ministry of Health on behalf of the Associate Minister of Health (Pharmac), Hon David Seymour.
The Government’s 100-day plan includes a commitment to “allow the sale of cold medication containing pseudoephedrine”. These papers begin the process to fulfil that commitment by progressing amendments to the Misuse of Drugs Act 1975 and the Medicines Regulations 1984 to reclassify pseudoephedrine.
Titles of Cabinet papers:
- Allowing sales of cold medicines containing pseudoephedrine
- Misuse of Drugs (Pseudoephedrine) Amendment Bill 2024: Approval for Introduction
Titles of minutes:
- Report of the Cabinet 100-Day Plan Committee: Period Ended 19 January 2024 (CAB-24-MIN-0002)
- Allowing sales of cold medicines containing pseudoephedrine (100-24-MIN-0003)
- Report of the Cabinet Legislation Committee: Period Ended 16 February 2024 (CAB-24-MIN-0037)
- Misuse of Drugs (Pseudoephedrine) Amendment Bill and Medicines (Pseudoephedrine) Amendment Regulations (LEG-24-MIN-0002)
Titles of briefings:
- Briefing: Allowing access to pseudoephedrine (H2023033231).
- Briefing: Draft Cabinet paper to allow access to pseudoephedrine (H2023034337).
- Briefing: Draft LEG paper: Misuse of Drugs (Pseudoephedrine) Amendment Bill 2024 (H2024035134).
Some information has been redacted where it is out of scope of this proactive release, and to protect the privacy of natural persons under Section 9(2)(a) of the Official Information Act.
The associated regulatory impact statement is available: Allowing sales of cold medicines containing pseudoephedrine.
